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Docosahexaenoic acidDietary deﬁciency of docosahexaenoic acid (C22:6 n-3; DHA) is linked to the neuropathology of several cognitive
disorders, including anxiety. DHA, which is essential for brain development and protection, is primarily obtained
through the diet or synthesized from dietary precursors, however the conversion efﬁciency is low. Curcumin
(diferuloylmethane), which is a principal component of the spice turmeric, complements the action of DHA in
the brain, and this study was performed to determinemolecularmechanisms involved.We report that curcumin
enhances the synthesis of DHA from its precursor, α-linolenic acid (C18:3 n-3; ALA) and elevates levels of
enzymes involved in the synthesis of DHA such as FADS2 and elongase 2 in both liver and brain tissues. Further-
more, in vivo treatment with curcumin and ALA reduced anxiety-like behavior in rodents. Taken together, these
data suggest that curcumin enhances DHA synthesis, resulting in elevated brain DHA content. These ﬁndings
have important implications for human health and the prevention of cognitive disease, particularly for popula-
tions eating a plant-based diet or who do not consume ﬁsh, a primary source of DHA, since DHA is essential for
brain function and its deﬁciency is implicated in many types of neurological disorders.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Docosahexaenoic acid (DHA, C22:6 n-3) is the most prevalent
omega 3 (n-3) fatty acid in the brain tissue, and its deﬁciency is linked
to several neurocognitive disorders such as anxiety-like behavior [1,2],
Alzheimer's disease [3], major depressive disorder [4], schizophrenia
[5] with psychosis [6] and impaired attention [7,8]. Extensive reports
using rodent models have identiﬁed that deﬁciency of DHA during
growth and development causes signiﬁcant learning and memory im-
pairments [2,9–12]. In addition to being critical for brain development
[13–17] dietary DHA is particularly important during challenging situa-
tions such as aging [18–21], or brain injury [22,23]. Notably, low levels
of DHA are associated with generalized anxiety [4] and supplementation
with DHA has been shown to have anxiolytic effects [24–27]. Thus, n-3
fatty acids play a critical role in brain health and the overall prevention
of cognitive disease.
Omega-3 fatty acids require n-3 fatty acid precursors for de novo
synthesis in mammals and therefore n-3 fatty acids must be obtained
through the diet. The n-3 fatty acids DHA and eicosapentaenoic acid
EPA (C20:5 n-3) can be obtained directly from animal sources or cane Biology and Physiology, 621
ax: +1 310 206 9693.
.be synthesized from plant derived n-3 fatty acid precursors. Primary
sources of DHA are ﬁsh and seafood. Sources of the precursor for DHA
and EPA, α-linolenic acid (C18:3 n-3; ALA), include sunﬂower and
soybean oil (N50% of the fat) [28]. DHA synthesis from its precursors
ALA, EPA and docosapentaenoic acid (C22:5 n-3; DPA) mainly takes
place in the liver since the synthesis of DHA in the brain is very limited
[29]. In general, the conversion efﬁciency of DHA synthesis from ALA is
quite low [30–32]. Vegetarians and vegans thus have reduced plasma
DHA compared to omnivores [33–36], yet many populations thrive on
an entirely plant based diet and are able to obtain adequate levels of
DHA to support cognitive development and plasticity. This raises the
question as to whether other food components commonly obtained in
the vegetarian diet might enhance the conversion of DHA from n-3
precursors. There is a discrepancy between animal studies showing
cognitive impairment associated with DHA deﬁciency and human
data reporting that vegetarians have normal cognitive abilities. We
conducted an investigation asking whether components commonly
consumed in traditional vegetarian diets could enhance DHA content
in the brain and the synthesis of DHA from plant-based sources.
Turmeric (Curcuma longa) is native to Southeast India, and the yellow
curry spice derived from the plant is a staple in Indian cooking. Ironically,
DHA is poorly consumed in India based on the vegetarian prevalence in
the population. Turmeric contains the polyphenolic secondarymetabolite
curcumin, which has been implicated to improve brain health including
reducing degeneration in Alzheimer's disease [19,37–39], ischemia [40]
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antioxidant and anti-inﬂammatory effects in various tissues [44–50],
we recently showed that curcumin prevents reduced DHA content in
the brain following brain trauma, beneﬁting brain plasticity as well as
reducing oxidative damage [22]. Additionally, while curcumin + DHA
had additive beneﬁcial effects on plasticity, behavior and brain DHA
content, the combined supplementation with curcumin + DHA reduced
the brain content of theDHAprecursor n-3DPA, raising the question as to
whether curcumin stimulates the synthesis of DHA [22]. Therefore, the
standing question is what are the molecular mechanisms by which
curcuminwould support the action of DHA on brain function and plastic-
ity under homeostatic conditions. Here we explore the possibility that
curcumin increases the production of DHA by inﬂuencing precursors
such ALA and DPA.
2. Experimental procedures
2.1. Animals
Male Sprague–Dawley rats (Charles River Laboratories, Inc.,
Wilmington, MA) weighing between 200 and 240 g were singly
housed and maintained in environmentally controlled rooms
(22–24 °C) on a 12 h light/dark cycle. All experiments were per-
formed in accordancewith theUnited StatesNational Institute ofHealth
Guide for the Care andUse of Laboratory Animals andwere approved by
the University of California at Los Angeles Chancellor's Animal Research
Committee.
2.2. Feeding study
After 1 week of acclimatization on standard chow, the rats (n =
5–6/group) were fed control diet (CTL), ALA diet (ALA; 2.7% of fat),
curcumin diet (CUR, 500 ppm), or ALA + CUR diet (ALA, 2.7% of fat;
CUR, 500 ppm). The diet components, including fatty acid proﬁles are
shown in Table 1. Diets were custom made (Dyets Inc., Bethlehem,
PA) and provided to animals in powder ad libitum. After 3.5 weeks
of feeding of the respective diet, rats were sacriﬁced by decapitation,
and the brains were rapidly dissected out, frozen on dry ice, and storedTable 1
Composition of experimental diets.
Amount (g/100 g diet)
CTL diet ALA diet ALA + Cur diet
Ingredient
Alacid 710, acid casein 20 20 20
Cornstarch 15 15 15
Sucrose 10 10 10
Dextrose 19.9 19.9 19.9
Maltose–dextrin 15 15 15
Cellulose 5 5 5
Salt–mineral mix 3.5 3.5 3.5
Vitamin mix 1 1 1
L-cystine 0.3 0.3 0.3
Choline bitartrate 0.25 0.25 0.25
TBHQ 0.002 0.002 0.002
Fat sources
Hydrogenated coconut oil 8.1 7.45 7.45
Safﬂower oil 1.9 1.77 1.77
Flaxseed oil – 0.48 0.48
Curcumin – – 500 or 250 ppm
Fatty acid composition as a percentage of total fatty acids
Total saturated 82 79 79
Total monounsaturated 3 3 3
Linoleic acid (n-6) 15 15 15
α linoleic acid (n-3) – 2.8 2.8at−70 °C until use for biochemical analyses. One-half of each brainwas
used for immunoblotting and the other half for lipid analysis.
2.3. Elevated plus maze
The elevated plus maze (EPM) test was performed as described by
Walf and Frye [51]. Brieﬂy, the EPM apparatus is made of laminated
wood consisting of 2 opposing open arms (10 × 50 cm) and 2 opposing
closed arms (10 × 50 cmwith 30 cm high walls). The maze was placed
60 cm above the ﬂoor and enclosed with curtains. An overhead video
camera was used to record behavior over a period of 5 min. Each rat
was placed in the middle of the maze pointed toward the open arm
that faced away from the experimenter. The time spent and the number
of entries into each arm was recorded using AnyMaze video tracking
software (San Diego Instruments, San Diego, CA). Data are reported as
time spent in the open arm (seconds).
2.4. Immunoblotting
The total proteins from the hippocampus were extracted. Protein
samples were separated by electrophoresis on an 8% polyacrylamide
gel and electrotransferred to a nitrocellulose membrane. Non-speciﬁc
binding sites were blocked in TBS, overnight at 4 °C, with 2% BSA and
0.1% Tween-20. Membranes were rinsed for 10 min in a buffer solution
(0.1% Tween-20 in TBS) and then incubatedwith anti-FADS2, anti-Elov2
(elongase 2), anti-4HNE and anti-β-actin (1:1000, Santa Cruz Biotech-
nology, Santa Cruz, CA), followed by anti-goat or anti-rabbit IgG horse-
radish peroxidase-conjugate (Santa Cruz Biotechnology, Santa Cruz,
CA). Immunocomplexes were visualized by chemiluminescence using
an ECL kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ) according
to the manufacturer's instructions. The ﬁlm signals were digitally
scanned and then quantiﬁed using NIH Image software.
2.5. Lipid analysis
Total lipids were extracted from cerebral tissues or cultured cells
with lysis solution of chloroform–methanol (2:1, vol:vol) containing
0.005% butylated hydroxytoluene in a ratio of sample to lysis solution
of 1:20 (i.e. 100mg tissue+ 2mL lysis solution). Samples were homog-
enized and extracted overnight at 4 °C, then centrifuged for 5 min at
1200 ×g and the supernatant was aspirated and transferred to a new
tube. 1 mL of lysis solution was added to the pellet and the centrifuga-
tion was repeated and the supernatant collected. To the combined
supernatant solution, 0.2 mL of 0.9% sodium chloride solution was
added and the liquid centrifuged at 2170×g for 15min at 4 °C. The chlo-
roform layer was transferred to a new 15mL tube, and thenmixedwith
an additional 0.2mL 0.9% saline. After centrifugation again for 10min at
2170 ×g at 4 °C, the chloroform layer was transferred to another 15 ml
tube and evaporated under nitrogen gas. The sample of total lipids was
dissolved in 1 mL hexane and methylated by 14% boron triﬂuoride–
methanol reagent (1 mL) at 90oC for 1 h. Oxygen was displaced using
nitrogen gas. After cooling to 21 °C 1 mL of distilled deionized water
was added and samples were vortexed and allowed to set for 30 min
to separate the water from the organic layer. The organic layer was
transferred to a new tube and evaporated using nitrogen gas. Fatty
acid proﬁles were determined by using gas chromatography (GC).
The system consisted of a model Clarus 500 gas chromatograph
(PerkinElmer) with a built-in Autosampler. An Elite-WAX column
(60 m, 0.32-mm internal diameter, PerkinElmer) was used, with hydro-
gen as the carrier gas. GC oven temperature was initially held at 140 °C
for 2 min and raised with a gradient of 5 °C min−1 until 250 °C and
held for 10 min. The total run time is 34 min. The injector and detector
were maintained at 250 and 300 °C, respectively. A 1 μl sample of fatty
acid methyl esters (FAME) was injected in split injection mode with a
100:1 split ratio. Peaks of resolved fatty acidmethyl esterswere identiﬁed
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FAME Mix).2.6. In vitro study with cell culture
HepG2 liver cellswere grown inDMEM(Life Technologies)with 10%
fetal bovine serum (Life Technologies) and 100 units/mL penicillin and
100 μg/mL streptomycin (Life Technologies) for 2 days. Cells were
then treated with vehicle (0.5% ethanol in distilled deionized water),
DPA (Nu-Chek-Prep, Elysian, MN) (50 μM), or DPA + CUR (Sigma-Al-
drich, Saint Louis, MO) (10, 20, or 40 μM) for 48 h. A separate set of
cells were treated with FADS2 (Δ6-desaturase) inhibitor SC-26196
(Sigma-Aldrich, Saint Louis, MO) (2 μM) 30 min before treatment with
DPA (50 μM) + Cur (20 μM). At the end of each experiment, the cells
were harvested for immunoblotting or lipid analysis.2.7. Statistical analysis
For DHA, DPA (n-3), and protein levels, the valueswere converted to
percent of control and represented as the mean ± SEM. The data were
analyzed by one-way ANOVA followed by Tukey's post hoc test to adjust
for multiple comparisons. Correlations were performed using linear re-
gression. Statistical differences were considered signiﬁcant at p b 0.05.
All statistical analyseswere performedusing Prismversion 6.0 (Graphpad
software Inc.).A
C
Fig. 1. Curcumin combinedwith ALA increases DHA in the brain, which correlates with reduced
(A). ALA plus CUR signiﬁcantly increasedDHA levels at both 250 and 500 ppmdoses of CUR. The
ALA alone or CUR alone group (B). DHA in the brain was positively correlated with time spent
control (p b 0.05); #compared with indicated p b 0.05 (n = 5–6).3. Results
3.1. Curcumin increases DHA in the brain when consumed with the n-3
precursor ALA
Animals weremaintained on a diet supplemented with ALA (2.7% of
total fatty acids) or ALA + CUR (250 or 500 ppm). ALA alone or CUR
alone did not increase DHA content in the hippocampus compared to
control group (p N 0.05; Fig. 1A). However, when rats were fed
ALA + CUR, DHA content was signiﬁcantly higher (162 or 152% of CTL
for 250 or 500 ppm curcumin-fed animals, respectively) in ALA + CUR
than ALA alone group (p b 0.05; Fig. 1A). These ﬁndings suggest that
CUR may enhance the conversion of ALA to DHA in vivo and elevate
DHA content in brain. We assessed the relevance of the dietary inter-
vention on cognitive function using the elevated-plus maze, a measure
of anxiety-like behavior. We found that the time spent in the open
arm was signiﬁcantly higher in ALA + CUR groups compared with
ALA or CUR alone or CTL (p b 0.05; Fig. 1B). We regressed DHA content
of CTL measured in the hippocampus against elevated plus maze scores
and found a signiﬁcant positive correlation between brain DHA levels
and time spent in the open arms, indicating that DHA in the brain is
associated with reduced anxiety-like behavior (p b 0.05; Fig. 1C). We
quantiﬁed enzymes involved in the synthesis of DHA fromn-3 precursors
in the brain tissue using immunoblotting. The enzyme FADS2 is involved
in the desaturation process during the conversion of precursor ALA to
DHA. Elov2 is involved in the elongation steps during DHA synthesis. In
the brain we found that CUR alone increased levels of FADS2 (126% ofB
anxiety-like behavior. ALA alone and CUR alone did not increase DHA in the hippocampus
time in the open armwas signiﬁcantly higher in ALA+CUR groups comparedwith CTL or
in the open arm (C). CTL: control, ALA: α-linolenic acid, CUR: curcumin. *Compared with
CTL ALA CTL+CUR500 ALA+CUR250 ALA+CUR500
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Fig. 2. Curcumin increases FADS2 and Elov2 in the brain. Curcumin signiﬁcantly increased the levels of FADS2 (A) and Elov2 (B) with or without ALA as detected by immunoblotting.
Combined, ALA+ CUR 500 ppm increased both enzymesmore than 500 ppm in CUR alone or ALA+ CUR 250 ppm (A, B). FADS2: delta 6 desaturase, Elov2: elongase, HIP: hippocampus,
CTL: control, ALA: α-linolenic acid, CUR: curcumin. *Compared with control (p b 0.05); #compared with indicated p b 0.05 (n = 5–6).
954 A. Wu et al. / Biochimica et Biophysica Acta 1852 (2015) 951–961control, p b 0.05; Fig. 2A), and the presence of ALA in the diet increased
the effects of CUR at 500 ppm on FADS2 (150% of control, p b 0.05;
Fig. 2A), whereas ALA alone did not affect FADS2 levels. Though signiﬁ-
cantly elevated compared to CTL, CUR at a dose of 250 ppm with ALA
led to lower FADS2 (120% of CTL, p b 0.05) compared to the CUR
500 ppm+ ALA treatment group (Fig. 2A). CUR (500 ppm) also signiﬁ-
cantly elevated the levels of Elov2when provided alone (114% of control,
p b 0.05) or in combination with ALA (132% of control, p b 0.05; Fig. 2B).
CUR at a dose of 250 ppm + ALA led to lower Elov2 (105% of CTL,
p b 0.05) compared to ALA + CUR at a dose of 500 ppm (p b 0.05;
Fig. 2B). The enzymes FADS2 and Elov2 are involved in the synthesis of
n-6 fatty acids as well as n-3 fatty acids. Table 2 shows levels of n-3 and
n-6 fatty acids quantiﬁed in the brain tissue. The intermediates 18:2
n-6, 20:3 n-6 and 20:4 n-6 were elevated by CUR + ALA at the
250 ppm dose relative to CTL. Notably, 20:4 n-6 was elevated at both
doses of CUR + ALA relative to controls, however the n-6 end product
22:5 n-6 was not elevated by curcumin treatment whereas 22:6 n-3
was elevated in both groups. The n-3 EPA and DPA are not pictured be-
cause levels were too low for detection using our methods. Curcumin
has known antioxidant and anti-inﬂammatory activities, thus it is
possible that the effects of CUR+ALA are due to neuroprotective effects
of CUR rather than a direct product of enhanced DHA synthesis. We
sought to determine whether curcumin in the diet affects markers ofTable 2
Composition of fatty acids in the hippocampus.
CTL ALA CTL + CUR
Mean SE Mean SE Mean
C18:2 n-6 0.1335 0.0147 0.1354 0.0058 0.128
C20:3 n-6 0.1672 0.0158 0.1871 0.0139 0.1768
C20:4 n-6 4.9686 0.4334 4.7316 0.1831 5.4403
C22:5 n-6 (DPA) 0.6036 0.0896 0.3749 0.0170 0.52
C22:6 n-3 (DHA) 5.6981 0.3692 6.1008 0.0930 6.3589
CTL: control, ALA: α-linolenic acid, CUR: curcumin, CTL + CUR: control + curcumin (500 pmo
a Compared with CTL.
b Compared with ALA.
c Compared with CTL + CUR.lipid peroxidation using the lipid degradation product 4 hydroxynonenol
(4-HNE) as amarker. Curcumin alone did not affect levels of 4-HNE, how-
ever therewas a signiﬁcant reduction in 4-HNE in animals fedALA,which
was further elevated with the addition of CUR to the diet (Fig. 3). Taken
together these ﬁndings suggest that dietary CUR, when combined with
the ALA precursor, increases DHA in the brain, reduces anxiety-like be-
havior and increases the quantity of DHA processing enzymes in the
hippocampus.
3.2. Curcumin increases DHA synthesis in the liver
Since DHA ismainly synthesized in the liver, we sought to determine
the effects of CUR on hepatic DHA. Compared with CTL, ALA alone in-
creased DHA in the liver (136% of control, p N 0.05; Fig. 4A). CUR alone
did not affect DHA content in the liver (p N 0.05; Fig. 4A), however
hepatic DHA was signiﬁcantly increased when CUR was combined
with ALA (171% of CTL for the 500 ppm dose, 179% of CTL for the
250 ppm dose, p b 0.05; Fig. 4A). We measured levels of the enzymes
FADS2 and Elov2 in the liver to evaluate effects of CUR on enzymes
involved in hepatic DHA synthesis. CUR500ppm+ALA signiﬁcantly in-
creased the levels of FADS2 (132% of CTL, p b 0.05; Fig. 4B, D), whereas
CUR (250 ppm) further elevated FADS2 (161%of CTL) signiﬁcantlymore
than the CUR 500 ppm group (p b 0.05; Fig. 3B, D). CUR alone or inALA + CUR250 ALA + CUR500 p value
SE Mean SE Mean SE
0.01430 0.2106a,b,c 0.0210 0.1756 0.0082 b0.01
0.0178 0.2452a 0.0190 0.2343 0.0153 b0.01
0.4383 7.474a,b,c 0.5900 6.8812a,b 0.4099 b0.001
0.0467 0.5485 0.0570 0.4618 0.0709 ns
0.6617 9.249a,b,c 0.5481 8.662a,b,c 0.3948 b0.001
l).
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Fig. 3. The n-3 precursor ALA supports the antioxidant action of curcumin in the brain. In combination with dietary ALA, CUR signiﬁcantly reduces the lipid peroxidation product 4
hydroxynonenol (4-HNE). Representative bands fromWestern blot are shown. CTL: control, ALA: α-linolenic acid, CUR: curcumin *Compared with control (p b 0.05); #compared with
indicated p b 0.05 (n = 5–6).
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120% of control, respectively; p b 0.05; Fig. 4C–D). Similar to FADS2, CUR
250 ppm had greater Elov2 (159% of CTL) compared to CUR 500 ppm
(p b 0.05; Fig. 4C–D). Together these ﬁndings suggest that CURmay en-
hance the conversion of ALA to DHA in the liver. CUR alone did not re-
duce levels of the lipid peroxidation product 4 HNE, however inCTL ALA CTL+CUR500 ALA+CUR250 ALA+CUR500
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Fig. 4. Curcumin and ALA combined increases DHA andDHA-synthesis-related enzymes in the l
with CUR at both 250 and 500 ppm doses, whereas CUR alone did not elevate liver DHA conte
groups (B). Elov2 was higher in all CUR groups compared to other groups (C). Representative
ALA: α-linolenic acid, CUR: curcumin. *Compared with control (p b 0.05); #compared with indcombination with ALA levels of 4 HNE were signiﬁcantly reduced com-
pared with CTL and CTL+ CUR. ALA alone also reduced levels of 4-HNE
compared with CTL and there was a trend toward further reduction
when ALA was combined with CUR 250 or CUR 500 ppm (p= 0.1 and
0.2, respectively; Fig. 5). Levels of n-3 and n-6 fatty acids were quanti-
ﬁed in the liver and are presented in Table 3. In the liver, ALA, CURCTL ALA CTL+CUR500 ALA+CUR250 ALA+CUR500
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iver. ALA alone increases DHA in the liver, which is further elevatedwhenALA is combined
nt (A). FADS2 was signiﬁcantly increased in both ALA + CUR groups compared to other
bands for FADS2 and Elov2 (D). FADS2: delta 6 desaturase, Elov2: elongase, CTL: control,
icated p b 0.05 (n = 5–6).
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Fig. 5. The DHA precursor ALA supports the antioxidant action of curcumin in the liver. In combination with dietary ALA, CUR signiﬁcantly reduces the lipid peroxidation product 4
hydroxynonenol (4-HNE). Representative bands fromWestern blot are shown. CTL: control, ALA: α-linolenic acid, CUR: curcumin *Compared with control (p b 0.05); #compared with
indicated p b 0.05 (n = 5–6).
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n-6 but signiﬁcantly reduced levels of 20:4 n-6. Both CUR and ALA re-
duced C22:5 n-6 relative to CTL, whereas levels of C22:5 n-3 were in-
creased by ALA and in both ALA + CUR groups, though CUR + CTL
had no effect. Comparedwith CTL, ALA andCTL+CUR22:6 n-3was sig-
niﬁcantly increased in both CUR+ ALA groups. We sought next to cor-
roborate the action of these enzymes on the effects of CUR in isolated
liver cells in culture.
3.3. Curcumin enhances FADS2-dependent DHA synthesis in cultured
HepG2 cells
We treated cultured liver cells HepG2 with the DHA precursor n-3
DPA (50 μM) or DPA plus three different doses of CUR (10, 20, or
40 μM). In an initial experiment we treated the cells with the precur-
sor ALA + curcumin, however we found that in cultured liver cells
ALA + curcumin did not increase synthesis of DHA (data not shown).
Similar ﬁndings were previously reported indicating that treating
cultured HepG2 cells with ALA does not increase DHA synthesis [52].
The lack of existing fatty acid precursors such as DPA,which are present
in an in vivo study, causes FADS2 to preferentially bind to ALA, thus
levels of EPA and DPA accumulate while the ﬁnal conversion from
DPA → DHA is negligible [52]. The conversion of DPA → DHA by
FADS2 is the rate-limiting step in DHA synthesis from ALA, therefore
for our in vitro study cells were treated with DPA. The combination of
DPA + CUR (20 μM) signiﬁcantly increased DHA levels (132% of VEH)
compared to DPA treatment alone (p b 0.05; Fig. 6A). Lower doses of
CUR at doses of 10 μm did not have effects on DHA synthesis while
the higher dose tended to reduce DHA levels to 85% of VEH and signiﬁ-
cantly reduced DHA synthesis compared to the 20 μM dose. TheseTable 3
Composition of fatty acids in the liver. CTL: control, ALA: α-linolenic acid, CUR: curcumin, CTL
CTL ALA CTL + CUR
Mean SE Mean SE Mean
C18:2 n-6 4.4466 0.3013 3.5083 0.1161 3.2111
C20:3 n-6 0.4571 0.0602 0.3944 0.0218 0.3679
C20:4 n-6(AA) 9.1706 b,c 0.9311 5.9512a 0.1372 7.0566a
C22:5 n6 (DPA) 1.0274 b,c 0.0412 0.255a,c 0.0389 0.7852a,b
C22:5 n3 (DPA) 0.0982 0.0075 0.2437c 0.0150 0.0674b
C22:6 n3 (DHA) 1.6033 b 0.1886 2.1874a,c 0.1527 1.4885b
a Compared with CTL.
b Compared with ALA.
c Compared with CTL + CUR.results suggest that CUR has a dose speciﬁc effect on the conversion of
n-3 DPA to DHA. Protein levels of FADS2 and Elov2 were elevated by
CUR + DPA at all measured doses (Fig. 6B–D). Similar to the DHA con-
tent, the 20 μM dose caused a large increase in FADS2 (175% of VEH;
p b 0.05; Fig. 6B) which was signiﬁcantly greater than the 10 μM dose
(p b 0.05), and tended to be higher than the 40 μM dose. All doses of
CUR caused a greater increase in FADS2 compared with VEH or DPA
alone (Fig. 6B, D). Similarly, DPA + CUR increased the levels of
Elov2 at all three doses (p b 0.05; Fig. 6C–D). Finally, we sought to deter-
mine the role of FADS2 on the process underlying CUR-enhanced DHA
synthesis. Cultured HepG2 cells were pre-treatedwith the FADS2 inhib-
itor SC-26196 (2 μM) prior to adding DPA (50 μM) + CUR (20 μm) to
the culture media. The FADS2 inhibitor SC-26196 signiﬁcantly reduced
DHA levels in cells treated with DPA plus CUR (69% of DPA+ CUR con-
trol group p b 0.05; Fig. 7). Together these ﬁndings suggest that CUR
promotes hepatic DHA synthesis, in which the desaturase FADS2 plays
a critical role.
4. Discussion
Wereport novel data showing that curcumin elevatesDHA synthesis
from n-3 precursors in liver cells, and that in combination with dietary
ALA, curcumin increases DHA content in vivo in both the liver and the
brain. Enzymes involved in the synthesis of DHA, FADS2 and elongase
2, were concurrently elevated, suggesting that curcumin may increase
DHA content, in part, by increasing the pool of enzymes available to
facilitate the conversion from either ALA or DPA. In the liver, dietary
ALA elevated the DHA precursor n-3 DPA, whereas curcumin did not in-
crease levels of this precursor (Table 3). In support of this, we found that
inhibition of the FADS2 enzyme in liver cells attenuated increases in+ CUR: control + curcumin (500 pmol).
ALA + CUR 500 ppm ALA + CUR 250 ppm p value
SE Mean SE Mean SE
0.1403 4.1782 0.1213 3.8729 0.9998 ns
0.0383 0.4509 0.0149 0.4669 0.0429 ns
0.2734 6.9291a 0.1977 7.6216 0.2276 0.001
0.0646 0.2363a,c 0.0143 0.1807a,c 0.0383 b0.0001
0.0057 0.3208a,c 0.0347 0.3224a,c 0.0670 b0.0001
0.1217 2.7713a,b,c 0.1016 2.8746a,b,c 0.0960 b0.0001
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Fig. 6.DHA and DHA-synthesis-related enzymes are elevated by curcumin in cultured liver cells (HepG2). The combination of DPA (50 μM) and CUR (20 μM) signiﬁcantly increased DHA
levels compared to DPA treatment alone (A). CUR signiﬁcantly increased the enzyme FADS2 (B) and Elov2 (C) at all doses compared with DPA (50 μM) alone. DPA plus CUR at a dose of
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curcumin. In this study, we also report that elevated DHA content in
the brain associated with curcumin and ALA in the diet correlates with
reduced anxiety-like behavior. These ﬁndings have important implica-
tions for human health and the prevention of cognitive disease, particu-
larly for populations eating a plant-based diet or who do not consume
ﬁsh, a primary source of DHA, since DHA is essential for brain function
and its deﬁciency is implicated in many types of neurological disorders.
Structurally, DHA accounts for roughly one-third of the fatty acids in
the gray matter of the brain and is essential to normal healthy brainDPA+CUR20 DPA+CUR20+SC26196
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Fig. 7. FADS2 is essential to curcumin effects on DHA synthesis in hepatic HepG2 cells.
SC-26196, an inhibitor of FADS2, signiﬁcantly reduced the DHA levels in cells treated
with DPA plus curcumin compared to the cells with similar treatment except inhibitor
SC-26196. *p b 0.05.development [13–17]. Dietary deﬁciency of n-3 fatty acids during devel-
opmental years has detrimental effects on cognitive abilities [10,11,
53–55], but cognitive performance can be improved by increasing
brain DHA content [55]. Animal studies strongly suggest that dietary
deﬁciency of DHA increases the risk for neurocognitive disorders [56,
57], and that diets enriched with DHA fosters learning and memory
[18,58–62] and are protective against cognitive decline during aging
[18,20]. In humans, circulating DHA is signiﬁcantly related to cognitive
abilities during aging [63] and inversely associated with cognitive de-
cline [64].
While DHA can be obtained through animal sources in the diet,
vegetarians and vegans may face challenges getting adequate dietary
DHA [35]. Increasingly, vegetarianism and veganism are being adopted
in the Western world [65]. Circulating omega 3 fatty acids are lower in
vegetarians and non-ﬁsh eaters than in people who consume ﬁsh [66].
Furthermore, changes in farming practices and food consumption
have taken place over the last century such that the dietary n-3 fatty
content may be declining [67]. For example, aquaculture currently
accounts for nearly one-half of the seafood supply for human consump-
tion in the world, which is a large increase compared with the 1980's,
where aquaculture contributed only 9% or even in 2000 where ﬁsheries
made up 34% [68]. Terrestrial oilseeds [69] andmaize [70] are commer-
cially used inﬁsh feed,which can increase the ratio of n-6:n-3 in seafood
[71–74]. Other dietary sources of DHA, such as beef [75] and eggs [76]
have reduced DHA content when using the most prevalent farming
practices of grain corn feeding vs pasture-feeding. Thus, even for omni-
vores, obtaining DHA through the diet may be increasingly difﬁcult in
958 A. Wu et al. / Biochimica et Biophysica Acta 1852 (2015) 951–961the current modern food climate. Paradoxically, in Asia, vegetarianism
has been practiced for centuries without high incidence of cognitive im-
pairment. No ill effects were reported in pregnancy outcomes of South
Asian vegetarians vs North London omnivores [77] and Seventh Day
Adventists residing in the Southwestern United States reported signiﬁ-
cantly less negative emotion compared with omnivores, despite
reduced levels of DHA [78].
Due to the apparent discrepancy between animal studies showing
clear cognitive impairment associated with reduced DHA in the brain
and human data showing improved mental health in vegetarians, we
sought to investigate whether other components commonly consumed
in traditional vegetarian diets could enhance DHA content in the brain
and the synthesis of DHA from vegetarian sources. In India 31% of the
population is lacto-vegetarian or vegan [79]. Turmeric is a household
staple in India, with reported average daily consumption ranging from
0.24 g/person/day to as high as 4 g/person/day [80,81]. Curcumin,
which is a naturally polyphenolic compound found in turmeric has
multifaceted medicinal properties and has been implicated in helping
to treat several types of neurological disorders including Alzheimer's
disease [39,82,83], retinal diseases [84,85], Parkinson's disease [86,87],
stroke [88], brain injury [22,41,42] and psychiatric disorders [89–91].
We recently reported that curcumin supplementation promoted
increased DHA content in the brain following TBI, and that this effect
was associated with elevated levels of enzymes involved in DHA synthe-
sis [22].We therefore investigatedwhether curcumin enhancesDHA syn-
thesis from vegetarian precursors. Here we report that, when combined
with dietary ALA, curcumin increases the DHA content in both liver and
brain tissues. Furthermore, we found that the elevated DHA content
was associated with elevated levels of the enzymes FADS2 and elongase
2, which are important for DHA synthesis.
Emerging evidence indicates that hepatic DHA synthesis from ALA
increases the DHA supply to the brain, but the rate of DHA conversion
from its precursors is low [28,92]. This may be partially due to the fact
that the plant-derived omega 6 and omega 3 fatty acids, linoleic acid
(18:2 n-6;LA) and ALA, respectively, compete for enzymes to catalyze
the desaturation and elongation reactions in order to generate longer
fatty acid chains. There are two stages involved in the process of DHA
synthesis from ALA. The ﬁrst stage includes a series of elongation byFig. 8. Schematic of themammalian DHA synthesis pathway and the inﬂuence of curcumin. Cur
DHA levels in these tissues when fed in combination with ALA. In cultured liver cells, curcumin
enzyme. Thus we propose that curcumin enhances DHA synthesis by increasing levels of DHA
creased DHA content in the brain is a product of elevated DHA synthesis in the brain tissue or
Elov2: elongase, ALA: α-linolenic acid DPA: docosapentaenoic acid, DHA: docosahexaenoic acielongases such as Elov5 and desaturation by desaturases such as
FADS1 (Δ5-desaturase) and FADS2 (Δ6-desaturase) (Fig. 8). This results
in the conversion of ALA to eicosapentaenoic acid (C20:5 n-3; EPA). The
second stage involves the conversion from EPA to docosapentaenoic
acid (C22:5 n-3; DPA) and ultimately to DHA. In mammals, this pro-
cess involves elongation (by elongases), desaturation (FADS2), and
β-oxidation (by Acox1 and 17β-HSD4) [93]. In particular, the interme-
diate C22:5 n-3 is converted to C24:6 n-3, which is then retroconverted
to C22:6 n-3 (DHA) [94,95]. It has been reported that in order to achieve
similar amounts of long chain omega 3 fatty acids in the brain on anALA
enriched, vs a preformed EPA + DHA enriched diet, ALA needed to be
consumed at 33.5 times the amount [96]. The action of FADS2 and
Elov2 are important control points (enzymatic reaction-limitation)
during the synthesis of DHA. Excessive ALA consumption may inhibit
the activity of enzymes involved in DHA synthesis. In particular FADS2
is subject to competitive inhibition between substrates. For example,
administration of ALA to HepG2 cells results in increased accumulation
of EPA, but not DHA, consistent with competitive inhibition of FADS2 by
DPA [52].We found that,when combinedwith the vegetarian precursor
ALA, dietary curcumin increased levels of FADS2 and elongase 2 in both
liver and brain tissues. Accordingly, our results showed that curcumin
produced greater hepatic and central DHA increases compared to ani-
mals fed ALA alone. Thus, our data support that by increasing the level
of these key enzymes curcumin may enhance the conversion of ALA
to DHA, even when ALA levels are increased in the diet. Accordingly,
our in vitro data suggest that the effects of curcumin to enhanced
DHA synthesis are dependent on the effective functioning of FADS2
enzyme, suggesting that curcumin effects are partially at the level of
DHA synthesis.
We report that curcumin signiﬁcantly increased the synthesis of
DHA from DPA in cultured liver cells. These data strongly suggest that
curcumin increases the hepatic synthesis of DHA from its precursors.
Since the liver is the primary site for most of the DHA synthesis in the
body, this raises the question as to whether some of the health effects
of curcumin can be attributed to the synthesis of DHA. For example,
deﬁcient liver biosynthesis of DHA was linked to cognitive impairment
in Alzheimer's patients who showed reduced expression of enzymes
involved in DHA synthesis [3]. We report that feeding animals acumin elevates the enzymes FADS2 and Elov2 in both liver and brain tissues and increases
+ DPA increases DHA production, an action which is prevented by inhibiting the FADS2
processing enzymes in the liver and brain, though we cannot say for sure whether the in-
whether DHA produced in the liver is transported to the brain. FADS2: delta 6 desaturase,
d.
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liver and the brain. Furthermore, elevations in brain DHA were closely
associated with the reduced anxiety-like behavior tested by EPM.
These results are in agreementwith previous studies describing an asso-
ciation between DHA dietary deﬁciency and anxiety-like behavior [2].
Herein we report that curcumin elevates levels of DHA in the brain,
and that these effects required the presence of ALA in the diet. Curcumin
has been reported to cross the blood brain barrier [97,98], and to beneu-
roprotective [41,99–101]. It is known that DHA is an essential compo-
nent of nerve cell membranes [102,103], but the synthesis of DHA is
very limited in the brain [29]. Sources of DHA for the brain include
dietary sources such as ﬁsh and DHA synthesized by the liver from pre-
cursors such as ALA (C18:3 n-3), DPA (C22:5 n-3), EPA (C20:5 n-3), and
tetracosahexaenoic acid (C24:6 n-3) [104–107]. Our current study
provides new evidence indicating that curcumin increases levels of
enzymes FADS2 and elongase 2, which are involved in DHA synthesis,
in the brain tissue. Additionally, we found that brain levels of DHA and
DHA synthesis enzymes were enriched in animals fed curcumin
and ALA together, but were unchanged when rats were fed the
ALA-enriched diet without curcumin. Though the rate of synthesis is
low, the brain seems to have the capacity to synthesize DHA from ALA
[29]. Thus it is possible that curcumin elevates DHA in the brain, in
part, through de novo synthesis in the brain tissue. This possibility
warrants further investigation, though liver synthesis seems the more
likely contributor to increased brain pools of DHA, since curcumin is
highly metabolized in the liver [108]. From our current dataset, we
cannot exclude the possibility that observed elevations in brain DHA
comes from the liver, since curcumin also promotes the DHA synthesis
in the liver.
Curcumin has known antioxidant, anti-inﬂammatory and anti-
apoptotic properties (for review see [109]), thus we cannot exclude
the possibility that elevated levels of DHA measured in the brain and
liver are the indirect result of reduced oxidative stress or anti-
inﬂammatory properties of curcumin. For example, oxidative stress is
inversely related to liver FADS2 and Δ5 desaturase activities and it has
been hypothesized that reduction in plasma antioxidant activity may
promote the direct inactivation or reduced expression of liver FADS2
[110]. Thus, the effect of curcumin on levels of FASD2may be indirectly
related to its antioxidant properties. During oxidative stress free radi-
cals generate lipid degradation products, such as 4-HNE. We measured
levels of 4-HNE in brain and liver tissues as a biomarker of oxidative
stress. Surprisingly, curcumin alone did not reduce 4-HNE in the brain
or liver, suggesting that curcumin alone in the diet did not reduce
lipid peroxidation under homeostatic conditions. In these terms, it is
likely that the antioxidant action of curcumin may be more prevalent
under challenging conditions such as brain injury. Treatment with
ALA either alone or in combinationwith curcumin signiﬁcantly reduced
levels of 4-HNE. In the brain tissue, the combined treatment of ALA and
curcumin further reduced lipid peroxidation, whereas in the liver it did
not. Interestingly, ALA alone was associated with elevated DHA in the
liver, but not in the brain. Therefore, if levels of DHA contributed to
the reduced lipid peroxidation, we would expect the differences be-
tween the ALA group and the ALA + CUR groups to be greater in the
brain compared with the liver, which is what the data show. Herein
we report that curcumin + ALA elevates levels of enzymes related to
DHA synthesis, elevates levels of DHA in the brain and liver, as well as
reduces n-6 precursors in the liver, suggesting that it is likely that
curcumin increases the synthesis of DHA from the ALA precursor
in vivo; further studies are warranted to elucidate whether affecting
synthesis is the mechanism by which curcumin enhances DHA levels
in the liver and brain.
5. Conclusions
The n-3 fatty acids DHA and EPA are essential for human health
that are obtained through dietary animal sources or synthesized fromprecursors. We provide evidence that curcumin enhances the biosyn-
thesis of hepatic DHA from n-3 precursors and enhances DHA accretion
in the brain. These data provide a novel insight into a potential mecha-
nism by which curcumin ameliorates neurocognitive disease.
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